Our company is composed of personnel with experience and expertise in the entire drug development cycle,
and based on this, we aim to develop innovative immuno-anticancer drugs.

In particular, we are developing various target-based drugs that induce the control of the tumor microenvironment and the functional recovery of cytotoxic T cells, which are major factors that cause the problems of existing immune checkpoint inhibitors (low reactivity and drug resistance).